ReviewRedox biology2019
Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase.
Review in Redox biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Metabolic syndrome confers a higher risk of oral cancer: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Therapeutic Modulation of Nitric Oxide Pathways to Address Insulin Resistance in Cardiovascular-Kidney-Metabolic Syndrome.International journal of molecular sciences · 2026Review
- Integrating dietary patterns and metabolomics with machine learning for metabolic syndrome risk assessment in a rural population.NPJ science of food · 2026Article
- Exploring XDH expression as a prognostic marker for urothelial carcinoma.Discover oncology · 2026Article
- Serum uric acid and its metabolism-a vital factor in the inflammatory transformation of cancer.Journal of advanced research · 2026Review
- Role of urate transporters in the kidneys and intestine in uric acid homeostasis.Kidney research and clinical practice · 2026Article
- Hydroxychavicol in Combination with 5-Fluorouracil Induced Apoptosis by Inhibiting Purine Metabolism in HT-29 and DLD-1 Cell Lines.Chinese journal of integrative medicine · 2026Article
- Gene mutation in metabolism syndrome with hematologic tumor: A retrospective cohort study.Clinical and experimental medicine · 2026Observational
- Integrating Animal Experiments, Bioinformatics and Molecular Dynamics Stimulations to Explore the Potential Mechanism of Songyang Duanwu Tea Improving Metabolic Syndrome.Combinatorial chemistry & high throughput screening · 2026Article
- Xanthine oxidoreductase expression is diminished in breast cancer as a response to uric acid mediated chelation of redox active iron.Free radical biology & medicine · 2025Article
- Serum xanthine oxidoreductase and oxidative stress are associated with bladder cancer: a case-control study from Jordan.Journal of applied biomedicine · 2025Article
- Risk factors for cancer among patients with type 2 diabetes: a retrospective cohort study.BMC cancer · 2025Article
- Purine metabolism-associated key genes depict the immune landscape in gout patients.Discover oncology · 2025Article
- Exploring the Therapeutic Potential ofJournal of clinical medicine · 2025Review
- Perilipin2-dependent lipid droplets accumulation promotes metastasis of oral squamous cell carcinoma via epithelial-mesenchymal transition.Cell death discovery · 2025Article
- Association of "a body shape index" with the risk of developing colorectal cancer in U.S. patients with metabolic syndrome: evidence from the NHANES 1999-2018.BMC gastroenterology · 2024Article
- Association between coffee consumption and metabolic syndrome in Korean adults.European journal of clinical nutrition · 2024Article
- Hyperuricemia and its related diseases: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024Review
- Exploring the causal association between uric acid and lung cancer in east Asian and European populations: a mendelian randomization study.BMC cancer · 2024Article
- Genetic prediction of the relationship between metabolic syndrome and colorectal cancer risk: a Mendelian randomization study.Diabetology & metabolic syndrome · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity and related pathologies such as diabetes and metabolic syndrome are associated with chronic inflammation and cancer. The serum level of xanthine oxidoreductase (XOR) is correlated to obesity-associated metabolic disorders. XOR can play a role in the pathogenesis of both metabolic syndrome and cancer through the inflammatory response and the oxidative stress elicited by the products of its activity. The reactive oxygen and nitrogen species and the uric acid derived from XOR concur to the development of hypertension, dyslipidemia and insulin resistance and participate in both cell transformation and proliferation, as well as in the progression and metastasis process. Despite the availability of different drugs to inhibit in vivo XOR activity, the complexity of XOR inhibition effects should be carefully considered before clinical application, save in the case of symptomatic hyperuricemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.